Pharming Group (FRA:PHGN) Gross-Profit-to-Asset % : 69.37% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Pharming Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharming Group's annualized Gross Profit for the quarter that ended in Mar. 2025 was €261.9 Mil. Pharming Group's average Total Assets over the quarter that ended in Mar. 2025 was €377.5 Mil. Therefore, Pharming Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 69.37%.

Pharming Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharming Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Gross-Profit-to-Asset % Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

54.00

45.22

47.12

48.85

62.01

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															41.82	61.98	63.70	80.31	69.37

Competitive Comparison of Pharming Group's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharming Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharming Group's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Pharming Group Gross-Profit-to-Asset % Calculation

Pharming Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	250.02	/	( (424.437	+	381.986)	/ 2 )
	=	250.02	/	403.2115
	=	62.01 %

Pharming Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	261.852	/	( (381.986	+	372.942)	/ 2 )
	=	261.852	/	377.464
	=	69.37 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Pharming Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharming Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (FRA:PHGN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines